27818 Federal Register / Vol. 72, No. 95 / Thursday, May 17, 2007 / Notices 

The annual reporting burden is as 

follows: 

Estimated Number of Respondents: 

250; 

Estimated Number of Responses per 

Respondent: 1; 

Average Burden Hours Per Response: 

.0.3674; and 

Estimated Total Annual Burden 

Hours Requested: 91.85. 

The annualized cost to respondents is 

estimated at: $5,218. There are no 

Capital Costs, Operating Costs and/or 

Maintenance Costs to report. 

A.12–1.—ESTIMATES OF HOUR BURDEN

Type of 

respondents 

Number of 

respondents 

Frequency of 

response 

Average time 

per 

response 

Annual hour 

burden 

Physicians (internists) ...................................................................................... 250 1 0.3674 91.85

Total .......................................................................................................... 250 ........................ ........................ 91.85 

Request for Comments: Written 

comments and/or suggestions from the 

public and affected agencies are invited 

on one or more of the following points: 

(1) Whether the proposed collection of 

information is necessary for the proper 

performance of the function of the 

agency, including whether the 

information will have practical utility; 

(2) The accuracy of the agency’s 

estimate of the burden of the proposed 

collection of information, including the 

validity of the methodology and 

assumptions used; (3) Ways to enhance 

the quality, utility, and clarity of the 

information to be collected; and (4) 

Ways to minimize the burden of the 

collection of information on those who 

are to respond, including the use of 

appropriate automated, electronic, 

mechanical, or other technological 

collection techniques or other forms of 

information technology. 

FOR FURTHER INFORMATION CONTACT: To 

request more information on the 

proposed project or to obtain a copy of 

the data collection plans and 

instruments, contact Dr. Marion Danis, 

Department of Clinical Bioethics, 

Building 10, room 1C118, National 

Institutes of Health, Bethesda, MD 

20892, or call non-toll-free number 301–

435–8727 or e-mail your request, 

including your address to: 

mdanis@cc.nih.gov. 

Comments Due Date: Comments 

regarding this information collection are 

best assured of having their full effect if 

received within 60-days of the date of 

this publication. 

David K. Henderson, 

Deputy Director, Warren G. Magnuson 

Clinical Center, National Institutes of Health. 

Ezekiel J. Emanuel, 

Director, Department of Clinical Bioethics, 

Warren G. Magnuson Clinical Center, 

National Institutes of Health. 

[FR Doc. E7–9543 Filed 5–16–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

Public Health Service, HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing in the U.S. in accordance with 

35 U.S.C. 207 to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

ADDRESSES: Licensing information and 

copies of the U.S. patent applications 

listed below may be obtained by writing 

to the indicated licensing contact at the 

Office of Technology Transfer, National 

Institutes of Health, 6011 Executive 

Boulevard, Suite 325, Rockville, 

Maryland 20852–3804; telephone: 301/ 

496–7057; fax: 301/402–0220. A signed 

Confidential Disclosure Agreement will 

be required to receive copies of the 

patent applications. 

Humanized Anti-Carcinoma CC49 

Monoclonal Antibodies 

Description of Technology: The 

technology describes the humanization 

of a murine anti-carcinoma antibody 

CC49 which has been shown to react 

with Tumor Associated Glycoprotein 72 

(TAG–72), an antigen which is 

expressed on human breast, ovarian, 

colorectal, and other carcinomas. 

The invention includes a new method 

of humanization of a rodent antibody 

which is based on grafting all the 

Complementarity Determining Residues 

(CDRs) of a rodent antibody onto a 

human antibody framework. 

Additionally, the method identifies 

Specificity Determining Residues 

(SDRs), the amino acid residues in the 

hypervariable regions of an antibody 

that are most critical for antigen binding 

activity and of rendering any antibody 

minimally immunogenic in humans by 

transferring the SDRs of the antibody to 

a human antibody framework. The 

resulting humanized antibodies, 

including CDR variants thereof 

(including a CH2 deleted version), are 

also embodied in the invention, as are 

methods of using the antibodies for 

therapeutic and diagnostic purposes. 

Furthermore, these antibodies are 

suitable for radiolabeling for the 

application in radioimmunotherapy 

(RIT) based treatment of several cancers. 

Phase I results of radioimmunotherapy 

for ovarian cancer using 90Yttrium-CC49 

murine monoclonal antibodies have 

shown promising results and confirms 

feasibility of the use of these antibodies 

for RIT. Promising pharmacokinetic data 

for the radiolabeled humanized 

antibodies in colon carcinoma xenograft 

models were recently published. 

Applications and Modality 

1. A humanized anti-cancer CC49 

monoclonal antibody has been 

developed. 

2. New methods of humanization of 

rodent antibodies have been identified. 

3. The antibody(s) has been shown to 

react with Tumor Associated 

Glycoprotein 72 (TAG–72), an antigen 

which is expressed on human breast, 

ovarian, colorectal, and other 

carcinomas. 

4. These antibodies are suitable for 

radiolabeling for the application in 

radioimmunotherapy (RIT) based 

treatment of several cancers. 

5. These antibodies can be useful in 

diagnosis and treatment of several 

cancers. 

Development Status: The technology 

is currently in the pre-clinical stage of 

development. Phase I results of 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 72, No. 95 / Thursday, May 17, 2007 / Notices 27819 

radioimmunotherapy for ovarian cancer 

using 90Yttrium-CC49 murine 

monoclonal antibodies have shown 

promising results and confirms 

feasibility of the use of these antibodies 

for radioimmunotherapy (RIT). 

Inventors: Syed V. Kashmiri (NCI), 

Eduardo A. Padlan (NIDDK), Jeffrey 

Schlom (NCI). 

Publications 

1. RD Alvarez et al. A Phase I study 

of combined modality 90Yttrium-CC49 

intraperitoneal radioimmunotherapy for 

ovarian cancer. Clin Cancer Res. 2002 

Sep; 8(9):2806–2811. 

2. A Forero et al. A novel monoclonal 

antibody design for 

radioimmunotherapy. Cancer Biother 

Radiopharm. 2003 Oct;18(5):751–759. 

3. PC Chinn et al. Pharmacokinetics 

and tumor localization of (111) inlabeled HuCC49DeltaC(H)2 in BALB/c 

mice and athymic murine colon 

carcinoma xenograft. Cancer Biother 

Radiopharm. 2006 Apr;21(2):106–116. 

Patent Status 

1. U.S. Patent No. 6,818,749 issued 

November 16, 2004 and U.S. Patent 

Application 10/927,433 filed August 25, 

2004 as well as issued and pending 

foreign counterparts [HHS Ref. No. E–

259–1998]; 

2. European Patent No. 00365997 

issued September 14, 1994 and its 

counterpart in Japan [HHS Ref. Nos. D–

003–1992/0–EP–07 and D–003–1992/0–

JP–05]; 

3. U.S. Patent No. 5,472,693 issued 

December 5, 1995 [HHS Ref. No. D–003–

1992/2–US–01]; 

4. U.S. Patent No. 6,051,225 issued 

April 18, 2000 [HHS Ref. No. D–003–

1992/3–US–01]; 

5. U.S. Patent No. 5,993,813 issued 

November 30, 1999 [HHS Ref. No. D–

003–1992/2–US–02]; 

6. U.S. Patent No. 6,641,999 issued 

November 4, 2003 [HHS Ref. No. D–

003–1992/2–US–04]; 

7. European Patent No. 628078 issued 

December 8, 1999 and its counterparts 

in Japan, Canada and Australia [HHS 

Ref. Nos. D–004–1992/0–EP–06, D–004–

1992/0–JP–03, D–004–1992/0–CA–04 

and D–004–1992/0–AU–05]; 

8. U.S. Patent No. 5,877,291 issued 

March 2, 1999 [HHS Ref. No. D–004–

1992/1–US–01]; 

9. U.S. Patent No. 5,892,020 issued 

April 6, 1999 [HHS Ref. No. D–004–

1992/1–US–01] and its foreign 

counterparts; 

10. Taiwanese Patent No. 173667 

issued July 10, 2003 [HHS Ref. No. D–

001–1996/0–TW–03]; 

11. U.S. Patent No. 6,737,060 issued 

May 18, 2004 [HHS Ref. No. D–001–

1996/1–US–03]; 

12. U.S. Patent No. 6,737,061 issued 

May 18, 2004 [HHS Ref. No. D–001–

1996/1–US–04]; 

13. U.S. Patent No. 6,753,152 issued 

June 22, 2004 [HHS Ref. No. D–001–

1996/1–US–05]; 

14. U.S. Patent No. 6,752,990 issued 

June 22, 2004 [HHS Ref. No. D–001–

1996/1–US–06]; 

15. U.S. Patent No. 6,329,507 issued 

December 11, 2001 [HHS Ref. No. D–

001–2006/0–US–01] and 

16. U.S. Patent No. 6,071,515 issued 

June 6, 2000 [HHS Ref. No. D–001–

2006/0–US–03]. 

Licensing Availability: Available for 

exclusive and non-exclusive licensing. 

Licensing Contact: Michelle Booden, 

PhD.; 301/451–7337; 

boodenm@mail.nih.gov 

Collaborative Research Opportunity: 

The National Cancer Institute’s 

Laboratory of Tumor Immunology and 

Biology is seeking statements of 

capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize anti-carcinoma 

antibodies. Please contact John D. 

Hewes, Ph.D. at 301–435–3121 or 

hewesj@mail.nih.gov for more 

information. 

Enhanced T-cell Activation by 

Costimulation: an Effective 

Immunotherapy for Cancer and 

Infectious Diseases 

Description of Technology: Cancer 

immunotherapy is a recent approach 

where tumor associated antigens 

(TAAs), which are primarily expressed 

in human tumor cells and not expressed 

or minimally expressed in normal 

tissues, are employed to generate a 

tumor specific immune response. 

Specifically, these antigens serve as 

targets for the host immune system and 

elicit responses that result in tumor 

destruction. The initiation of an 

effective T-cell immune response to 

antigens requires two signals. The first 

one is antigen specific via the peptide/ 

major histocompatibility complex and 

the second or ‘‘costimulatory’’ signal is 

required for cytokine production, 

proliferation, and other aspects of T-cell 

activation. 

The present technology describes 

recombinant poxvirus vectors encoding 

at least three or more costimulatory 

molecules and TAAs. The use of three 

costimulatory molecules such as B7.1, 

ICAM–1 and LFA–3 (TRICOM) has 

been shown to act in synergy with 

several tumor antigens and antigen 

epitopes to activate T cells. The effects 

with TRICOM were significantly 

greater than with one or two 

costimulatory molecules. Laboratory 

results support the greater effect of 

TRICOM to activate both CD4+ and 

CD8+ T cells. The invention also 

describes the use of at least one target 

antigen or immunological epitope as an 

immunogen or vaccine in conjunction 

with TRICOM. The antigens include 

but are not limited to carcinoembryonic 

antigen (CEA), prostate-specific antigen 

(PSA), and MUC–1. 

The combination of CEA, MUC–1, and 

TRICOM is referred to as PANVAC

and the combination of PSA and 

TRICOM is referred to as PROSTVAC. 

Licensing Availability: The technology 

is available for exclusive and nonexclusive licensing in combinations and 

for different fields of use. Some 

potential licensing opportunities are as 

follows: 

1. TRICOM (alone or with a 

transgene for a tumor antigen and/or an 

immunostimulatory molecule); 

2. The antigens only, including but 

not limited to CEA, PSA, and MUC–1; 

3. PANVAC and/or PROSTVAC; 

and 

4. Recombinant fowlpox-GM–CSF. 

Application(s) and Modality: Vectorbased TRICOM (alone or with a 

transgene for a tumor antigen and/or an 

immunostimulatory molecule), 

PANVAC and PROSTVAC and 

combinations thereof can be a potential 

novel immunotherapeutic approach for 

the treatment of cancer and infectious 

diseases. 

Advantages 

1. The technology is beyond proof-ofconcept, supported by laboratory results 

and publications. 

2. Phase I and Phase II clinical data 

available. 

3. Fewer validation studies are 

required compared to other 

immunotherapy related technologies. 

Development Status: Phase I and 

Phase II results available for poxvirus 

recombinants containing transgenes for 

TRICOM, CEA–TRICOM, PANVAC, 

and PROSTVAC. Further clinical 

studies are ongoing for other 

combinations. 

Inventors: Jeffrey Schlom (NCI) et al. 

Publications 

1. Kaufman HL, Cohen S, Cheung K, 

DeRaffele, Mitcham J, Moroziewicz D, 

Schlom J, and Hesdorffer C. Local 

delivery of vaccinia virus expressing 

multiple costimulatory molecules for 

the treatment of established tumors. 

Human Gene Ther. 17:239–244, 2006. 

2. Kantoff PW GL, Tannenbaum SI, 

Bilhartz DL, Pittman WG, Schuetz TJ. 

Randomized, double-blind, vectorcontrolled study of targeted 

immunotherapy in patients (pts) with 


pwalker on PROD1PC71 with NOTICES
27820 Federal Register / Vol. 72, No. 95 / Thursday, May 17, 2007 / Notices 

hormone-refractory prostate cancer 

(HRPC). 2006 ASCO Annual Meeting 

Proceedings, Part I, abstract 2501. J Clin 

Oncol.; 24. 

3. Marshall J, Gulley JL, Arlen PM, 

Beetham PK, Tsang KY, Slack R, Hodge 

JW, Doren S, Grosenbach DW, Hwang J, 

Fox E, Odogwa L, Park S, Panicali D, 

Schlom J. A phase I study of sequential 

vaccinations with fowlpox-CEA(6D)- 

TRICOM (B7–1/ICAM–1/LFA–3) alone 

and sequentially with vacciniaCEA(6D)-TRICOM, with and without 

GM–CSF, in patients with CEAexpressing carcinomas. J Clin Oncol. 

23:720–731, 2005. 

4. Palena C, Foon KA, Panicali D, 

Yafal AG, Chinsangaram J, Hodge JW, 

Schlom J, and Tsang KY. A potential 

approach to immunotherapy of chronic 

lymphocytic leukemia (CLL): enhanced 

immunogenicity of CLL cells via 

infection with vectors encoding for 

multiple costimulatory molecules. 

Blood 106:3515–3523, 2005. 

5. Gulley J, Todd N, Dahut W, Schlom 

J, Arlen P. A phase II study of 

PROSTVAC–VF vaccine, and the role of 

GM–CSF, in patients (pts) with 

metastatic androgen insensitive prostate 

cancer (AIPC) [abstract]. J Clin Oncol. 

2005; 23 (16S Pt 1): 2504. 

6. Yang S, Hodge JW, Grosenbach DW, 

and Schlom J. Vaccines with enhanced 

costimulation maintain high avidity 

memory CTL. J. Immunol. 175:3715–

3723, 2005. 

7. Yang S, Tsang KY, and Schlom J. 

Induction of higher avidity human CTL 

by vector-mediated enhanced 

costimulation of antigen-presenting 

cells. Clin Cancer Res. 11:5603–5615, 

2005. 

8. Hodge JW, Chakraborty M, KudoSaito C, Garnett CT, Schlom J. Multiple 

costimulatory modalities enhance CTL 

avidity. J Immunol. 174:5994–6004, 

2005. 

9. Tsang K–Y, Palena C, Yokokawa J, 

Arlen PM, Gulley JL, Mazzara GP, Gritz 

L, Go ́mez Yafal A, Ogueta S, Greenhalgh 

P, Manson K, Panicali D, and Schlom J. 

Analyses of recombinant vaccinia and 

fowlpox vaccine vectors expressing 

transgenes for two human tumor 

antigens and three human costimulatory 

molecules. Clin Cancer Res. 11:1597–

1607, 2005. 

10. Chakraborty M, Abrams SI, 

Coleman CN, Camphausen K, Schlom J, 

Hodge JW. External beam radiation of 

tumors alters phenotype of tumor cells 

to render them susceptible to vaccinemediated T-cell killing. Cancer Res. 

64:4328–4337, 2004. 

11. Zeytin HE, Patel AC, Rogers CJ, et 

al. Combination of a poxvirus-based 

vaccine with a cyclooxygenase-2 

inhibitor (celecoxib) elicits antitumor 

immunity and long-term survival in 

CEA.Tg/MIN mice. Cancer Res. 

64:3668–3678, 2004. 

12. Palena C, Zhu M–Z, Schlom J, and 

Tsang K–Y. Human B cells that 

hyperexpress a triad of costimulatory 

molecules via avipoxvector infection: an 

alternative source of efficient antigenpresenting cells. Blood 104:192–199, 

2004. 

13. Kudo-Saito C, Schlom J, and 

Hodge JW. Intratumoral vaccination and 

diversified subcutaneous/intratumoral 

vaccination with recombinant 

poxviruses encoding a tumor antigen 

and multiple costimulatory molecules. 

Clin Cancer Res. 10:1090–1099, 2004. 

14. Hodge JW, Poole DJ, Aarts WM, 

Gomez Yafal A, Gritz L, and Schlom J. 

Modified vaccinia virus ankara 

recombinants are as potent as vaccinia 

recombinants in diversified prime and 

boost vaccine regimens to elicit 

therapeutic antitumor responses. Cancer 

Res. 63:7942–7949, 2003. 

15. Hodge JW, Grosenbach DW, Aarts 

Wm, Poole DJ, and Schlom J. Vaccine 

therapy of established tumors in the 

absence of autoimmunity. Clin Cancer 

Res. 9:1837–1849, 2003. 

16. Aarts WM, Schlom J, and Hodge 

JW. Vector-based vaccine/cytokine 

combination therapy to enhance 

induction of immune responses to a 

self-antigen and anti-tumor activity. 

Cancer Res. 62:5770–5777, 2002. 

17. Hodge JW, Sabzevari H, Yafal AG, 

Gritz L, Lorenz MG, Schlom J. A triad 

of costimulatory molecules synergize to 

amplify T-cell activation. Cancer Res. 

59: 5800–5807, 1999. 

Patent Status 

1. U.S. Patent No. 6,969,609 issued 

November 29, 2005 as well as issued 

and pending foreign counterparts [HHS 

Ref. No. E–256–1998/0]; 

2. U.S. Patent Application No. 11/ 

321,868 filed December 30, 2005 [HHS 

Ref. No. E–256–1998/1]; and 

3. U.S. Patent No. 6,756,038 issued 

June 29, 2004 as well as issued and 

pending foreign counterparts [HHS Ref. 

No. E–099–1996/0]; 

4. U.S. Patent No. 6,001,349 issued 

December 14, 1999 as well as issued and 

pending foreign counterparts [HHS Ref. 

No E–200–1990/3–US–01]; 

5. U.S. Patent No. 6,165,460 issued 

December 26, 2000; as well as issued 

and pending foreign counterparts [HHS 

Ref. No E–200–1990/4–US–01]; 

6. U.S. Patent No. 7,118,738 issued 

October 10, 2006 as well as issued and 

pending foreign counterparts [HHS Ref. 

No E–154–1998/0–US–07]; 

7. PCT Application No. PCT/US97/ 

12203 filed July 15, 1997 [HHS Ref. No 

E–259–1994/3–PCT–02]; 

8. U.S. Patent Application Nos. 10/ 

197,127 and 08/686,280 filed July 17, 

2002 and July 25, 1996 [HHS Ref. No E–

259–1994/3–US–08 and /4–US–01]; 

9. U.S. Patent No. 6,946,133 issued 

September 20, 2005 as well as issued 

and pending foreign counterparts [HHS 

Ref. No E–062–1996/0–US–01]; 

10. U.S. Patent Application No. 11/ 

606,929 filed December 1, 2006 [E–062–

1996/0–US–11]; 

11. U.S. Patent Nos. 6,893,869, 

6,548,068 and 6,045,802 issued May 17, 

2005, April 15, 2003 and April 4, 2000 

respectively, as well as issued and 

pending foreign counterparts [HHS Ref. 

Nos. E–260–1994/1–US–03, US–02, US–

01]; and 

12. U.S. Patent. Application No. 11/ 

090,686 filed March 8, 2005 [HHS Ref. 

No E–260–1994/1–US–04]. 

Licensing Contact: Michelle Booden, 

PhD, 301/451–7337; 

boodenm@mail.nih.gov. 

Cooperative Research and 

Development Agreement (CRADA) 

Opportunity: A CRADA partner for the 

further co-development of this 

technology is currently being sought by 

the Laboratory of Tumor Immunology 

and Biology, Center for Cancer 

Research, NCI. 

The CRADA partner will: 

1. Generate and characterize 

recombinant poxviruses expressing 

specific tumor-associated antigens, 

cytokines, and/or T-cell costimulatory 

factors, 

2. Analyze the recombinant 

poxviruses containing these genes with 

respect to appropriate expression of the 

encoded gene product(s), 

3. Supply adequate amounts of 

recombinant virus stocks for preclinical 

testing, 

4. Manufacture and test selected 

recombinant viruses for use in human 

clinical trials, 

5. Submit Drug Master Files detailing 

the development, manufacture, and 

testing of live recombinant vaccines to 

support the NCI-sponsored INDs, 

6. Supply adequate amounts of 

clinical grade recombinant poxvirus 

vaccines for clinical trials conducted at 

the NCI Center for Cancer Research 

(CCR), and 

7. Provide adequate amounts of 

vaccines for extramural clinical trials 

through a clinical agreement with the 

Division of Cancer Treatment and 

Diagnosis, NCI. 

NCI will: 

1. Provide genes of tumor-associated 

antigens, cytokines and other 

immunostimulatory molecules for 

incorporation into poxvirus vectors, 

2. Evaluate recombinant vectors in 

preclinical models alone and in 

combination therapies, 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 72, No. 95 / Thursday, May 17, 2007 / Notices 27821 

3. Conduct clinical trials of 

recombinant vaccines alone and in 

combination therapies, and 

4. Provide Drug Master Files currently 

supporting the clinical use of the 

recombinant poxvirus vaccines. 

If interested in the above described 

CRADA, please submit a statement of 

interest and capability to Kevin Chang, 

PhD, in the NCI Technology Transfer 

Center at changke@mail.nih.gov or 301–

496–0477. 

Dated: May 11, 2007. 

Steven M. Ferguson, 

Director, Division of Technology Development 

and Transfer, Office of Technology Transfer, 

National Institutes of Health. 

[FR Doc. E7–9541 Filed 5–16–07; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Center for Complementary 

and Alternative Medicine; Notice of 

Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of the following 

meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel; Basic Science. 

Date: June 11–12, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Courtyard Marriott, Washingtonian 

Center, 240 Boardwalk Place (Rio), 

Gaithersburg, MD 20878. 

Contact Person: Dale L. Birkle, Ph.D, 

Scientific Review Administrator, Office of 

Scientific Review, National Center for 

Complementary, and Alternative Medicine, 

NIH, 6707 Democracy Blvd., Suite 401, 

Bethesda, MD 20892, (301) 451–6570. 

birkled@mail.nih.gov. 

Name of Committee: National Center for 

Complementary and Alternative Medicine 

Special Emphasis Panel; Centers of 

Excellence for Research on Complementary 

and Alternative Medicine. 

Date: June 20–22, 2007. 

Time: 8 a.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda Marriott, 5151 Pooks Hill 

Road, Bethesda, MD 20814. 

Contact Person: Martina Schmidt, Ph.D, 

Scientific Review Administrator, Office of 

Scientific Review, National Center for 

Complementary, and Alternative Medicine, 

NIH, 6707 Democracy Blvd., Suite 401, 

Bethesda, MD 20892, (301) 594–3456. 

schmidma@mail.nih.gov. 

Dated: May 8, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2427 Filed 5–16–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Open 

Meeting 

The National Eye Institute will host 

an Ocular Epidemiology Program 

Planning Panel Meeting to discuss 

research needs and opportunities in 

ocular epidemiology. The meeting will 

be open to the public. 

The thoughts and input from this 

meeting will be given by the panel 

members individually and incorporated 

into a report that will be given to the 

National Eye Institute. 

Name of Panel: Ocular Epidemiology 

Panel. 

Date: May 24–25, 2007. 

Time: 8 a.m.–5 p.m. 

Agenda: To discuss the Ocular 

Epidemiology Research. 

Place: Hyatt Regency Bethesda, One 

Bethesda Metro Center, (7400 Wisconsin 

Avenue), Bethesda, MD 20814. 

Contact Person: Mr. Michael Davis, 

Associate Director for Science Policy and 

Legislation, National Eye Institute, Bldg. 31; 

Room 6A25, 31 Center Drive MSC 2510, 

Bethesda, MD 20892, (301) 496–4308. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

Any interested person may file written 

comments with the panel by forwarding the 

statement to the Contact Person listed on this 

notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: May 8, 2007. 

Jennifer Spaeth, 

Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 07–2425 Filed 5–16–07; 8:45 am] 

BILLING CODE 4140–01–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. Appendix 2), notice 

is hereby given of a meeting of the 

National Advisory Eye Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Eye Council. 

Date: June 7, 2007. 

Closed: 8:30 a.m. to 10:30 a.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, 

Conference Room D, Bethesda, MD 20892. 

Open: 10:30 a.m. to Adjournment. 

Agenda: Following opening remarks by the 

Director, NEI there will be presentations by 

the staff of the Institute and discussions 

concerning Institute programs. 

Place: National Institutes of Health, 

Natcher Building, 45 Center Drive, 

Conference Room D, Bethesda, MD 20892. 

Contact Person: Lore Anne McNicol, PhD, 

Director, Division of Extramural Research, 

National Eye Institute, National Institutes of 

Health, Bethesda, MD 20892, (301) 451–2020. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 


pwalker on PROD1PC71 with NOTICES